STOCK TITAN

IO Biotech Announces Participation in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) announces participation in Jefferies London Healthcare Conference and Piper Sandler 35th Healthcare Conference. CEO Mai-Britt Zocca and CFO Amy Sullivan to attend one-on-one meetings in London. Fireside chat with CEO Mai-Britt Zocca at Piper Sandler conference in New York. Webcast link provided for the event. Webcast replay available on company's website for 90 days.
Positive
  • None.
Negative
  • None.

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences:

Event: Jefferies London Healthcare Conference
Location: London
One-on-one meetings: Wednesday, November 15, 2023
Participants: Mai-Britt Zocca, PhD, President and CEO and Amy Sullivan, CFO

Event: Piper Sandler 35th Healthcare Conference
Location: New York, New York
Fireside chat: Wednesday, November 29, 2023 at 4:30 pm ET
Presenter: Mai-Britt Zocca, PhD, President & CEO
Webcast link: https://event.webcasts.com/starthere.jsp?ei=1643140&tp_key=1d3631cba2

A webcast replay of the presentations will be available on IO Biotech’s website at www.iobiotech.com for 90 days following the presentation.

About IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® vaccine platform. The T-win platform is a novel approach to cancer vaccines designed to activate T cells to target tumor cells and immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line advanced melanoma data, IO102-IO103, in combination with pembrolizumab, has been granted a breakthrough therapy designation for the treatment of unresectable/metastatic melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.

About IO102-IO103

IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced non-small cell lung cancer and head and neck cancer (SCCHN), and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) evaluating IO102-IO103 plus pembrolizumab as a perioperative treatment in solid tumors including melanoma and SCCHN.

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

For further information, please visit www.iobiotech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing of the interim analysis of our Phase 3 trial, current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

Contact:
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com


FAQ

What conferences is IO Biotech participating in?

IO Biotech is participating in the Jefferies London Healthcare Conference and Piper Sandler 35th Healthcare Conference.

Who will attend the conferences from IO Biotech?

CEO Mai-Britt Zocca and CFO Amy Sullivan will attend the Jefferies London Healthcare Conference. CEO Mai-Britt Zocca will present a fireside chat at the Piper Sandler 35th Healthcare Conference.

Where can I watch the webcast of the Piper Sandler conference?

The webcast link for the Piper Sandler 35th Healthcare Conference is available at https://event.webcasts.com/starthere.jsp?ei=1643140&tp_key=1d3631cba2.

How long will the webcast replay be available?

The webcast replay will be available on IO Biotech's website for 90 days following the presentation.

IO Biotech, Inc.

NASDAQ:IOBT

IOBT Rankings

IOBT Latest News

IOBT Stock Data

49.41M
65.73M
0.24%
76.79%
0.31%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
COPENHAGEN